Segment 7 - The Complexities of Pathway Development
June 30th 2014Dr Sonnad inquired how replacing brand drugs with generic equivalents can affect pathway adherence. She also asked panelist to discuss the differences between early-stage and late-stage disease regimens, as well as the degree of flexibility there is in regimen design.
Read More
Segment 1 - Evidence-Based Decision Making and Clinical Pathway Adherence
June 30th 2014Seema Sonnad, PhD, associate editor for The American Journal of Managed Care, and director of Health Services Research at The Value Institute at Christiana Care Health System, led a panel discussion that focused on oncology clinical pathway adherence.
Read More
Segment 5 - Benefits and Risks Associated with Treatment
June 3rd 2014The conversation shifts from diagnosis of multiple myeloma to the various benefits and risks associated with treatment. Dr Chernew comments that multiple myeloma treatment is an area of great innovation, where options for patients are constantly changing.
Read More
Segment 9 - Challenges of Prior Authorization and Patient Access to RA Drugs
April 29th 2014The panelists concluded the discussion by analyzing the concept of a cost-sharing option for patients with RA. Conceptually, their out-of-pocket costs for certain medications would be based on their medication history.
Read More
Segment 8 - The Relation of Cost of RA Agents and Patient Adherence
April 29th 2014The panelists' discussion led to a conversation about quality and cost-effectiveness, especially as it relates to nonadherence. Dr Fendrick asked about the kinds of pressures patients face when it comes to paying for the drugs that they are prescribed.
Read More
Segment 7 - Making Decisions in the Use of Biologic Agents Versus Conventional Therapies
April 29th 2014When it comes to biologics like Rituxan and Remicade, which are intravenous infusions, decision making can be impacted by cost. Dr Fendrick asked the panelists what might hypothetically happen if cost was taken out of the equation when choosing between biologics and other RA treatments.
Read More
Segment 6 - Dosing of Methotrexate and Use of Other Agents
April 29th 2014The panelists weighed in on the use of newer agents as well as anticoagulants in RA treatment. Dr Fendrick noted his appreciation of the panelists' recognition of the fact that when it comes to agents, newer isn't always better.
Read More
Segment 3 - The Primary Care Physician's Role in RA Diagnosis
April 29th 2014This segment of the panel discussion focused on the role of primary care physicians (PCPs) in the early detection of RA symptoms. In particular, Dr Fendrick asked about the availability of protocolled guidelines that might help PCPs distinguish between RA and other kinds of arthritis.
Read More
Segment 1 - The Current State of Rheumatoid Arthritis in the United States
April 29th 2014Mark Fendrick, MD, co-editor-in-chief, The American Journal of Managed Care, professor, Division of General Medicine, Department of Internal Medicine and Department of Health Management and Policy, University of Michigan, moderated a discussion on the management and treatment of rheumatoid arthritis (RA).
Read More